PCAR-019 (anti-CD19 CAR-T cells)
Sponsors
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions
Acute Lymphocytic LeukemiaB-cell Prolymphocytic LeukemiaChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaFollicular LymphomaMantle Cell Lymphoma
Phase 1
CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
NCT02819583
Start: 2016-10-31End: 2019-09-30Target: 10Updated: 2016-10-25
Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma
NCT02851589
Start: 2016-07-31End: 2019-11-30Target: 10Updated: 2016-08-01